Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: March 24, 2026
Reporting Period: The filing announces financial results for the fiscal year ended December 31, 2025.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) containing the actual results. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not disclose specific material changes or comparative data versus the prior period. It serves only to notify the market of the issuance of the annual results press release.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the company issued a press release on March 24, 2026, regarding its 2025 results. No specific commentary, guidance, or outlook is included in the 8-K text itself.
Risks and Contingencies: The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual revenue, net income, and cash position figures for the year ended December 31, 2025.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not detailed in the 8-K body.
- Check for any forward-looking statements or updated guidance contained within the attached press release.
- Confirm the company's liquidity status and cash runway, as these are critical for a biotechnology firm and are not listed in this summary document.